Business Context and Reporting Period
Kura Oncology, Inc. filed a Form 8-K Current Report on June 6, 2016. The filing discloses the entry into two material definitive agreements on this date: an amendment to a license agreement with Janssen Pharmaceutica NV and an amendment to a management services agreement with Araxes Pharma LLC.
Key Financial Metrics
The filing does not provide specific revenue, profit, cash flow, margin, debt, or liquidity figures. The only financial metric disclosed relates to a change in a contractual fee:
- Management Fee Reduction: The monthly management fee payable by Araxes Pharma LLC to Kura Oncology was reduced from $100,000 to $65,000 per month.
Material Changes Versus Prior Period
The filing details two specific material changes effective as of June 6, 2016 (with the fee reduction retroactive to April 1, 2016):
- Janssen Amendment: Expanded the field of the license agreement with Janssen Pharmaceutica NV (originally dated December 18, 2014) to cover all human diseases, disorders, or medical conditions, excluding virology.
- Araxes Amendment: Reduced the monthly management fee under the agreement with Araxes Pharma LLC (originally dated October 1, 2014) by 35%.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, financial outlook, or specific risk factors beyond the standard disclaimer that the summary is qualified by reference to the full text of the amendments. The full text of the Janssen Amendment and Araxes Amendment is scheduled to be filed as exhibits to the Company's Quarterly Report on Form 10-Q for the period ending June 30, 2016.
Key Facts for Investor Verification
- Verify the specific terms and potential financial impact of the expanded license field with Janssen Pharmaceutica NV in the upcoming Form 10-Q.
- Confirm the retroactive application of the $35,000 monthly fee reduction from Araxes Pharma LLC starting April 1, 2016.
- Note that this 8-K does not contain comprehensive financial statements; refer to the Form 10-Q for the quarter ended June 30, 2016, for full financial data.